Clinical trial
Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX)
NCT00105976 · Merrimack Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00105976 |
|---|---|
| Title | Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX) |
| Official title | A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate |
| Lead sponsor | Merrimack Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | MM-093 |
| Enrollment | 260 |
| Start date | Feb 1, 2005 |
| First posted | Mar 21, 2005 |
| Last update posted | Jul 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: